# Stress Ulcer Prophylaxis Protocol

**Division of Acute Care Surgery**  
*Updated August 2024*

---

## 1. Background

Critically ill patients are at increased risk for gastrointestinal (GI) bleeding, primarily due to gastric or duodenal ulceration.  
- Overt bleeding risk: ~4.4%  
- Clinically significant bleeding: ~1.5%  
- Risk increases with **Injury Severity Score (ISS) >15** in trauma patients

### Definitive Indications for Prophylaxis:
1. Traumatic Brain Injury (TBI)  
2. Major Burn Injury  
3. Mechanical Ventilation >48 hours  
4. Coagulopathy  
   - INR > 1.5  
   - Platelets < 50,000

### Other Risk Factors:
- Alcohol use disorder  
- Acute hepatic failure  
- Sepsis  
- Acute renal failure  
- Trauma  
- Chronic NSAID use  
- High-dose steroids

Both **H2 receptor antagonists (H2RAs)** and **proton pump inhibitors (PPIs)** are acceptable agents for prophylaxis.  
- No conclusive evidence favoring one class over the other  
- **Enteral Nutrition (EN)** provides mucosal protection and should be initiated early when feasible

---

## 2. Indications for Prophylaxis

### A. High Risk — *Prophylaxis indicated for all patients*
- Mechanical ventilation >48 hours  
- Coagulopathy  
- Traumatic brain injury  
- Spinal cord injury  
- Significant burn injury (>20% TBSA)  
- History of prior GI hemorrhage

### B. Moderate Risk — *Consider prophylaxis if ≥2 present*
- Chronic NSAID or aspirin use  
- High-dose NSAID therapy  
  - Ibuprofen >1200 mg/day  
  - Naproxen >1000 mg/day  
  - Any scheduled ketorolac regimen  
- Sepsis  
- Vasopressor or inotrope requirement  
- Corticosteroids ≥ 250 mg/day hydrocortisone equivalent  
- New gastroduodenal or gastrojejunal anastomosis

### C. Low Risk or Tolerating PO Intake — *No prophylaxis needed*  
- Discontinue prophylaxis if previously initiated

---

## 3. Prophylaxis Algorithm

### A. Trauma Critical Illness

| Condition                               | Duration of Prophylaxis               |
|----------------------------------------|----------------------------------------|
| TBI, SCI, Burn                          | Continue for entire ICU stay           |
| Intubation >48h or Coagulopathy        | Discontinue when EN goal met (unless additional moderate risk factors persist) |

---

## 4. Medication Management

### First-Line Agent:

- **Famotidine 20 mg PO/PT/IV q12h**  
  - If **CrCl < 50 mL/min** → dose **q24h**

### Suspected or Confirmed Upper GI Bleed:

- **If enteral access available:**
  - Omeprazole 40 mg PO/PT q12h (oral suspension for DHT)
- **If no enteral access:**
  - Pantoprazole 40 mg IV q12h

---

## 5. Special Situations

### Continuation/Initiation for High-Risk NSAID Use:

- High-dose NSAIDs **plus** one or more of the following:
  - Anticoagulation  
  - Aspirin  
  - Corticosteroids  
  - Peptic ulcer disease  
  - History of H. pylori infection  
  - GI anastomosis  
  - Spinal cord injury  

- Consider switching to **celecoxib 100–200 mg BID** if patient can tolerate oral capsules

### Home PPI Use:

- **Resume home PPI** if patient was taking one prior to admission

---

## 6. References

1. Cook DJ et al. *Risk factors for gastrointestinal bleeding in critically ill patients.* N Engl J Med. 1994; 330(6):377–381.  
2. Cook DJ et al. *Sucralfate vs. ranitidine for GI bleeding in ventilated patients.* N Engl J Med. 1998; 338(12):791–797.  
3. Hurt RT et al. *Stress prophylaxis and enteral nutrition.* JPEN. 2012; 36(6):721–731.  
4. Guillamondegui OD et al. *EAST Guidelines for Stress Ulcer Prophylaxis.* 2008. [EAST.org](http://www.east.org/resources/treatment‐guidelines)  
5. Marik PE et al. *Stress ulcer prophylaxis review.* Crit Care Med. 2010; 38:2222–2228.  
6. Lin PC et al. *PPI vs. H2RA meta-analysis.* Crit Care Med. 2010; 38:1197–1205.  
7. Alhazzani W et al. *PPI vs. H2RA in critically ill.* Crit Care Med. 2013; 41:693–705.  
8. Liu Y et al. *Prophylaxis in non-ICU patients: network meta-analysis.* Clin Ther. 2020; 42(3):488–498.  
9. Marker M et al. *Pantoprazole in ICU GI bleeding.* N Engl J Med. 2018; 379(2):199–208.  
10. Gwee KA et al. *Co-prescribing PPIs with NSAIDs.* J Pain Res. 2018; 11:361–374.

---

## 7. Authors

- **Bradley Dennis, MD**  
- **Jill Streams, MD**  
- **Leanne Atchison, PharmD**  
- **Jennifer Beavers, PharmD**
